Dogwood Therapeutics Inc (DWTX)

DWTX future is looking very bright😎💰

$DWTX's Halneuron has shown statistically & clinically reduced pain in cancer-related pain & CINP #clinicaltrials, respectively. General cancer pain responders exhibited long-lasting relief & no evidence of addiction or tolerance in prior #clinicaltrials.https://t.co/2wkAfepxIr pic.twitter.com/SEtNnjnFxn— Dogwood Therapeutics (@DogwoodTher) March 3, 2026

DWTX LONG😎💰

HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target

DWTX...$3.03...🥳

georgie18

Member Level
Re: None

Saturday, January 10, 2026 12:24:04 PM

Post#
711201
of 711283
DWTX...$2.85...🥳... https://schrts.co/BVIrYvUW ...Bullish Descent Block Reversal Pattern on this Oversold Pincher Squeeze Chart...Read filings with S8... https://www.nasdaq.com/market-activity/stocks/dwtx/sec-filings

ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for up to approximately $12.5 million in gross proceeds through a registered direct offering (the “Registered Offering”) and a concurrent private placement (the “Private Offering” and, together with the Registered Offering, the “Offerings”) for the issuance of an aggregate of 4,386,037 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate of 4,386,037 shares of common stock, priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in-lieu thereof) is being sold together with one warrant to purchase one share of common stock at a combined purchase price of $2.85 (or $2.8499 per pre-funded warrant and accompanying warrant). The warrants will have an exercise price of $3.28 per share. The warrants will be exercisable upon shareholder approval, and will expire five and one-half years from the effective date of shareholder approval. Upfront gross proceeds from the Offerings are expected to be $12.5 million, before deducting commissions and offering expenses, with the potential for an additional $14.4 million in gross proceeds upon the exercise of the warrants at the election of investors and subject to shareholder approval.

The Registered Offering consists of the issuance and sale of 2,338,948 shares of common stock, and the Private Offering consists of the issuance and sale of pre-funded warrants to purchase 2,047,089 shares of common stock and warrants to purchase up to 4,386,037 shares of common stock.

Greg Duncan, Chairman and CEO of DWTX, commented: “We plan to utilize the net proceeds from the Offering to advance development of Halneuron® through the ongoing Phase 2b final data readout, while also pursuing strategic opportunities to further strengthen the Company’s research portfolio. We are executing with determination to advance the standard of care for patients suffering from chemotherapy induced pain and neuropathy, conditions for which there are no FDA approved treatments. This transaction represents a strong endorsement of our two first-in-class development candidates, Halneuron® and SP16, our research progress, growing IP portfolio and the exceptional talent we’ve assembled. Today’s offering provides DWTX with access to additional capital to support Phase 3 development.”

Maxim Group LLC is acting as the sole placement agent for the Offerings.

The Company intends to use the net proceeds from this offering to further advance the clinical development of Halneuron® and for working capital and general corporate purposes. The Offerings are expected to close on or about January 13, 2026 (the “Closing Date”), subject to the satisfaction of customary closing conditions.

The Registered Offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-287575) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on June 2, 2025. The Registered Offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the effective shelf registration statement. A prospectus supplement relating to the shares of common stock to be issued in the Registered Offering will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the Registered Offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate @Peter Sherman.

The pre-funded warrants and warrants described above were offered in a private placement under Section 4(a)(2) of the Act and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. Pursuant to a securities purchase agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock issuable upon exercise of the pre-funded warrants and warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron® and SP16 IV. Our lead product candidate, Halneuron®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron® is a non-opioid, NaV 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (“CINP”). SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (LRP1) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16 acts as an LRP1 agonist that in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CINP trial is fully funded by the National Cancer Institute.

Dogwood Therapeutic’s largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit www.dwtx.com.

I’m 99.99% positive these guys are going to get it done.😎 DWTX LONG💰

Halneuron® (TTX) = Nav1.7 channel blocker, analgesic best for treating established CINP pain
Halneuron® is in Phase 2b development for chemotherapy induced neuropathic pain
Opportunity to expand
Nav1.7 channel blocker should have utility on cancer related pain, as well as post surgical pain

SP16 = LRP1-agonist, anti-inflammatory, neuroprotection best for attenuation of CIPN during chemo;
SP16 is in early clinical stage development and may enable neuroprotection, may preserve full chemo
regimen and potential to synergistically complement Halneuron® in treating pain post chemotherapy
SP16 Phase 1b development for CIPN
Program is fully funded by NCI through next clinical milestone
Common commercial call points (oncology and pain centers) and potential partners
Bundled protocols/formularies with major cancer centers/providers
Co-promotion targeting infusion suites and pain clinics
Together deeper penetration into the global CIPN treatment opportunity ~$1.5B market
Ability to expand into larger ~$5B cancer pain market.

DWTX...$2.85...🥳... https://schrts.co/BVIrYvUW ...Bullish Descent Block Reversal Pattern on this Oversold Pincher Squeeze Chart...Read filings with S8... https://www.nasdaq.com/market-activity/stocks/dwtx/sec-filings

DWTX LONG💰

$DWTX is developing a breakthrough non-opioid pain management approach through its lead candidate, #Halneuron®.

Learn more: https://t.co/2wkAfeoZST#DogwoodTherapeutics #DWTX pic.twitter.com/R2fGbMtX9n— Dogwood Therapeutics (@DogwoodTher) January 8, 2026

2026 is going to be a great year for DWTX shareholders😎💰

DWTX LONG😎💰

H.C. Wainwright analyst Sean Lee has issued a "Buy" rating for Dogwood Therapeutics (DWTX), with recent target prices ranging from $10 to $12. The analyst's ratings are based on the company's clinical data and competitive positioning of its product candidates.

Analyst Opinion DetailsRating: Buy.
Price Targets: Lee has maintained various price targets, including $10, and later raised it to $12.
Rationale: The positive outlook is supported by promising clinical trial results for Dogwood's product candidates, such as the potential efficacy and favorable safety profile of certain treatments in ongoing studies.

DWTX😎💰

$DWTX announces positive results from an interim analysis of 97 patients who had completed treatment in the ongoing #Halneuron® Phase 2b chemotherapy induced neuropathic pain (#CINP) study.

Full press release here: https://t.co/X36MWAzlUu#ClinicalTrials #DWTX #Neuropathy pic.twitter.com/zm115I0bpq— Dogwood Therapeutics (@DogwoodTher) December 23, 2025

Shorts are going to get FRIED here😉 DWTX LONG💰

DWTX💰

The $DWTX team channels decades of pain medicine development and commercialization experience into advancing next generation therapies for patients.

Learn more here: https://t.co/2wkAfepxIr#ClinicalTrial #Halneuron #CINP #CIPN #Fibromyalgia pic.twitter.com/4XmlpsSjoA— Dogwood Therapeutics (@DogwoodTher) December 9, 2025

DWTX LONG😎💰

$DWTX's CEO, Greg Duncan, joined @WTjern to discuss his career in biotech, the formation of #DWTX, and the company’s innovative non-opioid pain management solution, #Halneuron.

Listen below:@Spotify: https://t.co/A5PXgFp66E@ApplePodcasts: https://t.co/6ztQSkGH3F pic.twitter.com/LEc3PFTCTu— Dogwood Therapeutics (@DogwoodTher) December 4, 2025

DWTX will be heading for a new 52 week high soon folks!!

Our lead product candidate, Halneuron®, is in Phase 2b development as a non-opioid, NaV 1.7 inhibitor to treat pain conditions including the neuropathic pain associated with chemotherapy treatment ("CINP"). Halneuron® has been granted fast track designation from the Food and Drug Administration ("FDA") for the treatment of CINP. Success in this Phase 2b study will serve as the basis for the Company engaging the FDA to align on the Halneuron® Phase 3 development program requirements.

"We plan to use synthetically manufactured Halneuron® in both Phase 3 development and commercialization," said Greg Duncan, Dogwood Therapeutics Chief Executive Officer. "This new synthetic process builds on our proprietary and best-in-class manufacturing know-how, with potential to reset our exclusivity period for 20 years, thus providing ample opportunity to deliver Halneuron's® full commercial potential."

This is exciting news!! DWTX LONG😎💰

$DWTX announced it has filed for new intellectual property protection for synthetic Halneuron®. If granted, the IP's exclusivity period will extend to 2045, before additional patent term restoration extensions.

Read more here: https://t.co/5fH8wRlKvz pic.twitter.com/b0pvczwmMC— Dogwood Therapeutics (@DogwoodTher) December 2, 2025

DWTX NEWS$$$$

- New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron®-

- New Synthetic Process to be Used for Phase 3 Development Provides Higher Manufacturing Yields and Reduces Costs Versus Naturally Harvested Halneuron® -

ATLANTA, GA / ACCESS Newswire / December 2, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has filed for new intellectual property protection for synthetic Halneuron®. If granted, the IP's exclusivity period will extend to 2045, before additional patent term restoration extensions.

"We plan to use synthetically manufactured Halneuron® in both Phase 3 development and commercialization," said Greg Duncan, Dogwood Therapeutics Chief Executive Officer. "This new synthetic process builds on our proprietary and best-in-class manufacturing know-how, with potential to reset our exclusivity period for 20 years, thus providing ample opportunity to deliver Halneuron's® full commercial potential."

About Halneuron®

Our lead product candidate, Halneuron®, is in Phase 2b development as a non-opioid, NaV 1.7 inhibitor to treat pain conditions including the neuropathic pain associated with chemotherapy treatment ("CINP"). Halneuron® has been granted fast track designation from the Food and Drug Administration ("FDA") for the treatment of CINP. Success in this Phase 2b study will serve as the basis for the Company engaging the FDA to align on the Halneuron® Phase 3 development program requirements.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq:DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron® and SP16 IV.

Our lead product candidate, Halneuron®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron® is a non-opioid, NaV 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain ("CINP").

SP16 IV is a low-density lipoprotein receptor related protein-1 (LRP1) agonist with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16 acts as an LRP1 agonist that in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CINP trial is fully funded by the National Cancer Institute.

For more information, please visit www.dwtx.com.

That’s cool bud. This is one of my long-term holds. This will be over $100/share one day.😎💰

I know David; I was only commenting on the two-day dropback after the runup. I'm still holding.

Same? We were trading under $5 last week.

same ole   same ole

Shorts could really get DESTROYED on this one.😎 DWTX💰

Agree. Hope the shorties don't swoop and take it back down.

Great news😎💰

https://ir.dwtx.com/news/press-releases/detail/141/dogwood-therapeutics-secures-exclusive-worldwide-royalty

https://ir.dwtx.com/news/press-releases/detail/140/dogwood-therapeutics-to-participate-in-fireside-chat-at-the

I’ll check it out👍 Thanks😎

AIMH SAME SS over 12 years off expert 4/25 Check the Q 6M Float target Brava Health Inc Nevada SOS

Which one bud?

DLR You have got to DD the one that's being accumulated 👁️

HUGE PARTNERSHIPS will be coming folks!! DWTX💰

Dogwood is also pioneering the antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID (“LC”) and fibromyalgia (“FM”). Overactive immune response related to activation of tissue resident herpesvirus has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel syndrome, LC, chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease, often triggered by events which compromise the immune system.

TICK TOCK DWTX LONGS😎💰

Dogwood’s lead product, Halneuron®, is a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain (CINP), cancer related pain (CRP), and other pain indications. Halneuron is a small molecule that reduces pain transmission by blocking Nav 1.7, a sodium channel involved with the initiation and conduction of nerve impulses in the peripheral nervous system.

Dog chit ???

NEWS!! DWTX💰

https://ir.dwtx.com/news/press-releases/detail/138/dogwood-therapeutics-announcesenrollment-of-first-fifty

It’s been very quiet here since April, which is fine by me😎 when this drug is through with these trials, Dogwood will either be bought out, or our stock price will be well over $100/Share💰 That’s not even including the drugs in the pipeline for fibromyalgia and long covid!! I’ll be very patient with this one.

Thanks. Glad you're happy. $10 is a start toward my own happiness. I'm semi-happy with a little hope. :)

HUGE NEWS: $DWTX

Price adjustment by HC WAINWRIGHT big powerhouse, BOSTON , MASSACHUSETTS

BUY rating given $10

TEN DOLLARS

This is GREAT, not pumping just happy!

Staircase continues here with $DWTX and Bull breakout with continuation.

My opinion!

Have nice day!

Respectfully,
Maverick
$DWTX

GO $DWTX !!!

Yes!! We’re going to stairstep up that way! $DWTX

putting a smile on my face, albeit a tiny one. I won't be really smiling until we break $13-$15. Any new news? I don't see any.

Up 73% this morning😉Volume is over 12 million in just 30 minutes!!Serious Accumulation happening!!DWTX LONG💰

Lumpina- Fair enough and appreciate your sincerity in your post! I hope you and your family have had a nice Easter, if you celebrate it.
You seem fair, and to the point so I’m cool with that.

Sometimes I get real pumped up on cool companies and stocks like this, thus I understand your pumping comments towards me, rightfully so.

I’m just seriously shocked how cheap this company is with their acquisitions and PHARMA products etc.
I know they did the offering, but feel it’s SEVERELY UNDERVALUED!
I hope you have a nice remainder of the weekend!
Respectfully,
Maverick
$DWTX

I'm not bitter Topgun - far from it. I have a big ole smile on my face as I type this. I try to be honest on this board, as opposed to the pumpers/dumpers who inundate us with non-factual posts. I'm here to make money, as I suppose your are - not to spread misinformation. So, positive vides to YOU and fellow shareholders. :)

So negative, sounds like you are TRAPPED from HIGHER PRICES when they did that OFFERING!

Stop being BITTER! Life’s to short, smile!

You might reconsider the wording of your post and change the first word from "when" to "If". Talk is cheap in the business world; words mean things. While I hope the partnership with someone DOES occur (and hopefully some company with very deep pockets), we'll have to wait and see, eh?

How long before the partnership is announced?

When the partnership news comes, this takes off and never gets below $20 again.😎💰

Kaboom 💥

I do LOVE this company and feel it’s SEVERELY UNDERVALUED!
$DWTX

MY opinion, not wanting to be a pumper, just SUPER EXCITED for all the potential this company has!!
All my opinion. , !

Respectfully,
Maverick

LOVE IT $DXF

Unreal I got to load another 3,000 shares below $8.21!!

MOASS MOTHER OF ALL SHORT SQUEEZES about to happen here !

$DXF

NAKED SHORT—- MAJOR

FAILURE TO DELIVERS- MILLIONS SHARES 2.7 MILLION

SHARES TO SHORT - ZIPPO

FLOAT 233,000 shares HAHA OWNED by COURAGEOUS LONGS in my OPINION!

$20 going once $30 going BWAHHH

FRY NAKED SHORTS IN BURNING BACON GREASE LOL!

$DXF going to HALT UP and continue making those NAKED SHORTS PAY FOR MESSING WITH $DXF!

Also , so amazing they thought they could “sale their long position in pre market and short single digit shares to SCARE FOLKS into selling …

BWAHHH!!

$DXF RIP YOUR FACE OFF SHORTS RELLY COMMENCES at market open!!

Look for yourself on FINTEL!

$DXF
💯🚀
4,200 STRONG MOASS $DXF

My opinion!
Maverick
$DXF


$DWTX
$TWOH
WOLVERINES 🚀🚀🚀